Skip to content
StockMarketAgent
Direct answer
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Stock analysis

ZTS fair value $109–$170

By StockMarketAgent.AI team· supervised by
Geanalyseerd: 2026-05-12Bijgewerkt: Volgende update: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
Koers
$76.94
▲ +62.83 (+81.66%)
Fair value
$140
$109–$170
Beoordeling
Sterk kopen
confidence 88/100
Opwaarts potentieel
+81.7%
upside to fair value
Veiligheidsmarge
$118.80
MoS level · 15%
Marktkapitalisatie
$32.3B
P/E fwd 10.3

§1 Samenvatting

  • Composite fair value $140 with high case $170.
  • Implied upside of 81.7% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$76.94Price
Low $109.15
Mid $139.77
High $170.49

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.

  • Intangible assets via unmatched patent
    Intangible assets via unmatched patent portfolio and brand loyalty.
  • High switching costs for veterinary
    High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
  • Cycle upside
    Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.

§2 Berenscenario

A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.

Hoe deze these kan breken

Margin Contraction

· Low

Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.

FV impact
Valuation compresses to the $109.15 low-end threshold.

Livestock Headwinds

· Medium

Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.

FV impact
Mild drag on terminal value generation and forward EPS.

Macro Demand Shock

· Medium

Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.

FV impact
Near-term EPS shock testing the $110 forward earnings scenario value.
Vroege waarschuwingssignalen om te volgen
MetriekHuidigTrigger-drempel
Operating margin contracting below 35% over two consecutive quarters.MonitorDeterioration versus the report thesis
Forward EPS growth turning negative.MonitorDeterioration versus the report thesis
ROIC dropping precipitously toward the 8.43% WACC.MonitorDeterioration versus the report thesis
Erosion of the 71.8% gross margin floor.MonitorDeterioration versus the report thesis
Accelerated generic approvals targeting core parasiticide or dermatology portfolios.MonitorDeterioration versus the report thesis

§3 Financiële historie

Winst-en-verliesrekening — laatste zes perioden

Post2022-12-312023-12-312024-12-312025-12-31Trend
Omzet$8.08B$8.54B+5.7%$9.26B+8.4%$9.47B+2.3%+5.4%
Brutowinst$5.63B$5.98B$6.54B$6.80B+6.5%
Bedrijfsresultaat$2.93B$3.07B$3.39B$3.60B+7.1%
Nettowinst$2.11B$2.34B+10.9%$2.49B+6.4%$2.67B+7.2%+8.1%
WPA (verwaterd)$4.49$5.07$5.47$6.02+10.3%
EBITDA$3.34B$3.67B$3.86B$4.07B+6.8%
R&D$539.0M$614.0M$686.0M$698.0M+9.0%
VAA$2.01B$2.15B$2.32B$2.38B+5.8%

Kwaliteitsscores

OCF / Nettowinst
1.09×
>1 wijst op hoge winstkwaliteit
Drempel boekhoudkwaliteit
Fail
Sector-aangepaste drempel
ROIC
22.5%
Rendement op geïnvesteerd kapitaal
Individuele abonnees — vanaf §411 extra secties

Lees de volledige analyse — 11 extra secties.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Volledig rapport voor elke gedekte ticker
24 maanden rating-archief
Watchlist-briefings + rating-wijzigingsmeldingen
PDF + DOCX-export in elke taal
Start gratis proefperiode
Op elk moment opzegbaar.
FAQ

ZTS — frequently asked questions

  1. Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Related coverage

Names readers of ZTS also follow

Same archetype: mature-compounder